Managing cancer pain, once it is refractory to conventional treatment, continues to challenge caregivers committed to serving those who are suffering from a malignancy. Although neuromodulation has a role in the treatment of cancer pain for some patients, these therapies may not be suitable for all patients. Therefore, neuroablative procedures, which were once a mainstay in treating intractable cancer pain, are again on the rise. This guideline serves as a systematic review of the literature of the outcomes following neuroablative procedures.

J. Bradley Elder, MD

Ahmed M. Raslan, MD

Jason M. Schwalb, MD

Mayur Sharma, MD